Treatment guidelines, such as those from the American Society of Clinical Oncology [10], National Comprehensive Cancer Network [11], and Japanese Breast Cancer Society [12], recommend that in patients with HER2-positive metastatic breast cancer, the standard first-line therapy should include the TRAS + PER + docetaxel combination and second-line therapy should include T-DM1. This evidence concerns the gene ERBB2 and breast cancer.